TherapeuticsMD
TXMD
146 hedge funds and large institutions have $932M invested in TherapeuticsMD in 2019 Q1 according to their latest regulatory filings, with 28 funds opening new positions, 59 increasing their positions, 30 reducing their positions, and 21 closing their positions.
97% more repeat investments, than reductions
Existing positions increased: 59 | Existing positions reduced: 30
33% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 21
31% more capital invested
Capital invested by funds: $711M → $932M (+$221M)
4% more funds holding
Funds holding: 140 → 146 (+6)
0.02% more ownership
Funds ownership: 1.57% → 1.59% (+0.02%)
8% less call options, than puts
Call options by funds: $2.55M | Put options by funds: $2.77M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Frontier Capital Management
Boston,
Massachusetts
|
+$23.1M |
| 2 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$16.6M |
| 3 |
NIP
Nicholas Investment Partners
Rancho Santa Fe,
California
|
+$5.01M |
| 4 |
DCM
Daruma Capital Management
New York
|
+$3.97M |
| 5 |
JP Morgan Chase
New York
|
+$3.17M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of New York Mellon
New York
|
-$33.6M |
| 2 |
BlackRock
New York
|
-$6.74M |
| 3 |
PA
Perceptive Advisors
New York
|
-$5.71M |
| 4 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
-$2.66M |
| 5 |
First Eagle Investment Management
New York
|
-$2.27M |
TXMD Hedge Fund Activity: Q1 2019 in Review
146 of the 4,632 institutional investors tracked by Wall St. Rank reported a position in TherapeuticsMD (TXMD) for Q1 2019, worth a combined $932M — up 31% from $711M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new TXMD positions and 21 closed out — a net gain of 7 holders — while 59 added to existing stakes and 30 trimmed.
The largest buyer was Frontier Capital Management, adding an estimated $23.1M. The largest seller was Bank of New York Mellon, cutting an estimated $33.6M.
- 146 institutional investors held TherapeuticsMD (TXMD) as of Q1 2019, up from 140 in Q4 2018.
- Funds reported $932M of TherapeuticsMD stock for Q1 2019, up 31% quarter-over-quarter.
- 28 funds opened new TherapeuticsMD positions in Q1 2019 and 21 closed out, a net change of +7 holders.
- The largest TherapeuticsMD buyer in Q1 2019 was Frontier Capital Management, an estimated $23.1M added.
- The largest TherapeuticsMD seller in Q1 2019 was Bank of New York Mellon, an estimated $33.6M sold.
Based on aggregated 13F filings for Q1 2019.